Gt Biopharma (GTBP) traded down -1.09 % during a 24 hours period ending at 01:20 AM Central Europe on Tuesday 27th. One Gt Biopharma stock can currently be bought for about USD 5.07 on popular exchanges. Current supply of Gt Biopharma stocks is 1.8 mn. Gt Biopharma has a current market capitalization of USD 9.9 mn and approximately USD 348.9 k worth of Gt Biopharma was traded on exchanges in the last 24 hours. Since last month end, Gt Biopharma has traded -20.06 % down. Simple moving average of last 200 days is at USD 1.65. The highest price of past 52 weeks was recorded at USD 11.98 on 09/14/2026. 52 weeks low was at USD 0.22 on 09/04/2026.
Here is how related stocks have performed in the past 24 hours:
Defi Capital Markets (DCM) traded down -2.86 % and now trades at USD 3.57. Current market capitalisation for Defi Capital Markets is USD 11.3 mn.
Karyopharm Therapeutics (KPTI) traded down -5.13 % and now trades at USD 0.48. Current market capitalisation for Karyopharm Therapeutics is USD 11.7 mn.
Actuate Therapeutics (ACTU) traded down -7.95 % and now trades at USD 0.53. Actuate Therapeutics has a market capitalisation of USD 11.4 mn.
Biofrontera (BFRI) traded up 1.02 % and now trades at USD 0.82. Current market capitalisation for Biofrontera is USD 11.7 mn.
Cellectar Biosciences (CLRB) traded up 4.27 % and now trades at USD 1.21. Current market capitalisation for Cellectar Biosciences is USD 11.5 mn.
About Gt Biopharma
GT Biopharma, Inc., based in Westlake Village, United States, is a health care biotechnology company that specializes in discovering, developing, and commercializing drugs for therapeutic molecular treatments of cancer, myeloma, osteolytic lesions, and other unmet medical needs globally.
